Cargando…

Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study

BACKGROUND: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Samuel, Ying, Jay, Liew, Gailina, Marshall, Wayne, Liew, Choong-Chin, Burakoff, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734158/
https://www.ncbi.nlm.nih.gov/pubmed/23876008
http://dx.doi.org/10.1186/1756-9966-32-44
_version_ 1782279485686546432
author Chao, Samuel
Ying, Jay
Liew, Gailina
Marshall, Wayne
Liew, Choong-Chin
Burakoff, Robert
author_facet Chao, Samuel
Ying, Jay
Liew, Gailina
Marshall, Wayne
Liew, Choong-Chin
Burakoff, Robert
author_sort Chao, Samuel
collection PubMed
description BACKGROUND: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum, ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided “blind spot”. METHODS: We previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I, 65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12; unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%); regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population. RESULTS: The panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95). CONCLUSION: This seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to enhanced CRC screening effectiveness.
format Online
Article
Text
id pubmed-3734158
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37341582013-08-06 Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study Chao, Samuel Ying, Jay Liew, Gailina Marshall, Wayne Liew, Choong-Chin Burakoff, Robert J Exp Clin Cancer Res Research BACKGROUND: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum, ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided “blind spot”. METHODS: We previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I, 65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12; unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%); regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population. RESULTS: The panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95). CONCLUSION: This seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to enhanced CRC screening effectiveness. BioMed Central 2013-07-23 /pmc/articles/PMC3734158/ /pubmed/23876008 http://dx.doi.org/10.1186/1756-9966-32-44 Text en Copyright © 2013 Chao et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Chao, Samuel
Ying, Jay
Liew, Gailina
Marshall, Wayne
Liew, Choong-Chin
Burakoff, Robert
Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title_full Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title_fullStr Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title_full_unstemmed Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title_short Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
title_sort blood rna biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734158/
https://www.ncbi.nlm.nih.gov/pubmed/23876008
http://dx.doi.org/10.1186/1756-9966-32-44
work_keys_str_mv AT chaosamuel bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy
AT yingjay bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy
AT liewgailina bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy
AT marshallwayne bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy
AT liewchoongchin bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy
AT burakoffrobert bloodrnabiomarkerpaneldetectsbothleftandrightsidedcolorectalneoplasmsacasecontrolstudy